Kymera Therapeutics Inc. Insider Trading

KYMR

Last 12 months

Insiders bought $172M and sold $243M on the open market.

90% of the selling was scheduled in advance under 10b5-1 plans. Director Bruce Booth sold $21.7M on Dec 12, 2025, 26% of their stake, outside a plan.

Net open-market

−$70.7M

1 buy · 41 sales

Under a 10b5-1 plan

90%

of the value sold

Insiders who bought / sold

1 / 10

executives and directors

Last open-market buy

Dec 2025

Dec 11, 2025

Get an email when KYMR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 1	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan 6 parts	30,000	$113.80 average	$3.41M	4.3%	Form 4
Sep 4	Brian Adams Chief Legal Officer	SoldNo plan 3 parts	6,371	$116.83 average	744K	11%	Form 4
Jul 7	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan	50,000	$119.00	$5.95M	7.0%	Form 4
Jul 1	Noah Goodman Chief Business Officer	Sold10b5-1 plan	3,389	$114.29	387K	6.7%	Form 4
Jul 1	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan 5 parts	80,000	$115.30 average	$9.22M	11%	Form 4
Jun 30	Bruce N. Jacobs Chief Financial Officer	Sold10b5-1 plan 8 parts	77,109	$114.97 average	$8.86M	24%	Form 4
Jun 29	Bruce Booth Director	Sold10b5-1 plan 14 parts	76,650	$108.05 average	$8.28M	14%	Form 4
Jun 29	Bruce Booth Director	Sold10b5-1 plan 8 parts	31,283	$109.48 average	$3.42M	6.3%	Form 4
Jun 26	Biotechnology Value Fund II LP Large holder	SoldNo plan 4 parts	1,630,658	$106.50 average	$174M	84%	Form 4
Jun 25	Bruce Booth Director	Sold10b5-1 plan 22 parts	285,684	$121.86 average	$34.8M	35%	Form 4
Jun 23 – 25	Bruce Booth Director	Sold10b5-1 plan 30 parts	398,765	$110.31 average	$44M	41%	Form 4
Jun 25	Noah Goodman Chief Business Officer	Sold10b5-1 plan 2 parts	5,000	$114.00 average	570K	9.1%	Form 4
Jun 22	Bruce Booth Director	Sold10b5-1 plan 4 parts	31,798	$103.75 average	$3.3M	4.9%	Form 4
Jun 17 – 22	Bruce Booth Director	Sold10b5-1 plan 29 parts	478,198	$94.72 average	$45.3M	44%	Form 4
Jun 22	Noah Goodman Chief Business Officer	Sold10b5-1 plan	2,500	$99.00	248K	4.7%	Form 4
May 26 – 27	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan 7 parts	17,184	$79.92 average	$1.37M	28%	Form 4
May 11	Elena Ridloff Director	Sold10b5-1 plan	3,000	$87.00	261K	100%	Form 4
Apr 29	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan 3 parts	30,000	$81.18 average	$2.44M	4.3%	Form 4
Apr 22	Bruce Booth Director	Sold10b5-1 plan 3 parts	6,000	$89.96 average	540K	0.9%	Form 4
Apr 22	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan	300	$90.00	27K	0.5%	Form 4
Apr 14 – 15	Bruce Booth Director	Sold10b5-1 plan 4 parts	9,494	$90.01 average	855K	1.4%	Form 4
Apr 14 – 15	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan 2 parts	6,551	$90.00 average	590K	9.7%	Form 4
Apr 14	Noah Goodman Chief Business Officer	Sold10b5-1 plan	1,347	$90.00	121K	2.6%	Form 4
Apr 9 – 10	Noah Goodman Chief Business Officer	Sold10b5-1 plan 4 parts	10,264	$87.47 average	898K	17%	Form 4
Mar 31 – Apr 1	Elena Ridloff Director	Sold10b5-1 plan 3 parts	12,000	$85.39 average	$1.02M	100%	Form 4
Mar 31 – Apr 1	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan 3 parts	22,240	$85.43 average	$1.9M	27%	Form 4
Mar 23 – 25	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan 6 parts	115,977	$78.02 average	$9.05M	65%	Form 4
Mar 20	Pamela Esposito Director	Sold10b5-1 plan 3 parts	2,500	$79.15 average	198K	100%	Form 4
Mar 11	Jeremy G Chadwick Chief Operating Officer	Sold10b5-1 plan 3 parts	25,758	$83.30 average	$2.15M	27%	Form 4
Mar 2 – 4	Jeremy G Chadwick Chief Operating Officer	SoldNo plan 7 parts	5,958	$86.54 average	516K	7.5%	Form 4
Mar 2 – 4	Jared Gollob Chief Medical Officer	SoldNo plan 7 parts	10,508	$87.24 average	917K	8.2%	Form 4
Mar 2 – 4	Bruce N. Jacobs Chief Financial Officer	SoldNo plan 7 parts	12,471	$87.50 average	$1.09M	5.1%	Form 4
Mar 2	Bruce Booth Director	Sold10b5-1 plan 2 parts	81,866	$90.13 average	$7.38M	11%	Form 4
Feb 25	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan 5 parts	30,000	$90.26 average	$2.71M	4.3%	Form 4
Feb 20	Pamela Esposito Director	Sold10b5-1 plan 2 parts	2,500	$87.31 average	218K	100%	Form 4
Jan 20	Pamela Esposito Director	Sold10b5-1 plan 3 parts	5,500	$67.91 average	374K	100%	Form 4
Dec 31, 2025	Nello Mainolfi Chief Executive Officer	Sold10b5-1 plan 2 parts	30,000	$78.06 average	$2.34M	4.3%	Form 4
Dec 17, 2025	Pamela Esposito Director	Sold10b5-1 plan 4 parts	27,563	$82.16 average	$2.26M	100%	Form 4
Dec 10, 2025 – Dec 12, 2025	Bruce Booth Director	SoldNo plan 14 parts	236,588	$91.72 average	$21.7M	26%	Form 4
Dec 11, 2025	Felix Baker Director	Bought 2 parts	2,005,813	$86.00 average	$172M	34%	Form 4

Oct 110b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 30,000 at avg $113.80
$3.41M
4.3% of stake
Sep 4No plan
Brian Adams
Chief Legal Officer · sold 6,371 at avg $116.83
744K
11% of stake
Jul 710b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 50,000 at $119.00
$5.95M
7.0% of stake
Jul 110b5-1 plan
Noah Goodman
Chief Business Officer · sold 3,389 at $114.29
387K
6.7% of stake
Jul 110b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 80,000 at avg $115.30
$9.22M
11% of stake
Jun 3010b5-1 plan
Bruce N. Jacobs
Chief Financial Officer · sold 77,109 at avg $114.97
$8.86M
24% of stake
Jun 2910b5-1 plan
Bruce Booth
Director · sold 76,650 at avg $108.05
$8.28M
14% of stake
Jun 2910b5-1 plan
Bruce Booth
Director · sold 31,283 at avg $109.48
$3.42M
6.3% of stake
Jun 26No plan
Biotechnology Value Fund II LP
Large holder · sold 1,630,658 at avg $106.50
$174M
84% of stake
Jun 2510b5-1 plan
Bruce Booth
Director · sold 285,684 at avg $121.86
$34.8M
35% of stake
Jun 23 – 2510b5-1 plan
Bruce Booth
Director · sold 398,765 at avg $110.31
$44M
41% of stake
Jun 2510b5-1 plan
Noah Goodman
Chief Business Officer · sold 5,000 at avg $114.00
570K
9.1% of stake
Jun 2210b5-1 plan
Bruce Booth
Director · sold 31,798 at avg $103.75
$3.3M
4.9% of stake
Jun 17 – 2210b5-1 plan
Bruce Booth
Director · sold 478,198 at avg $94.72
$45.3M
44% of stake
Jun 2210b5-1 plan
Noah Goodman
Chief Business Officer · sold 2,500 at $99.00
248K
4.7% of stake
May 26 – 2710b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 17,184 at avg $79.92
$1.37M
28% of stake
May 1110b5-1 plan
Elena Ridloff
Director · sold 3,000 at $87.00
261K
100% of stake
Apr 2910b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 30,000 at avg $81.18
$2.44M
4.3% of stake
Apr 2210b5-1 plan
Bruce Booth
Director · sold 6,000 at avg $89.96
540K
0.9% of stake
Apr 2210b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 300 at $90.00
27K
0.5% of stake
Apr 14 – 1510b5-1 plan
Bruce Booth
Director · sold 9,494 at avg $90.01
855K
1.4% of stake
Apr 14 – 1510b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 6,551 at avg $90.00
590K
9.7% of stake
Apr 1410b5-1 plan
Noah Goodman
Chief Business Officer · sold 1,347 at $90.00
121K
2.6% of stake
Apr 9 – 1010b5-1 plan
Noah Goodman
Chief Business Officer · sold 10,264 at avg $87.47
898K
17% of stake
Mar 31 – Apr 110b5-1 plan
Elena Ridloff
Director · sold 12,000 at avg $85.39
$1.02M
100% of stake
Mar 31 – Apr 110b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 22,240 at avg $85.43
$1.9M
27% of stake
Mar 23 – 2510b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 115,977 at avg $78.02
$9.05M
65% of stake
Mar 2010b5-1 plan
Pamela Esposito
Director · sold 2,500 at avg $79.15
198K
100% of stake
Mar 1110b5-1 plan
Jeremy G Chadwick
Chief Operating Officer · sold 25,758 at avg $83.30
$2.15M
27% of stake
Mar 2 – 4No plan
Jeremy G Chadwick
Chief Operating Officer · sold 5,958 at avg $86.54
516K
7.5% of stake
Mar 2 – 4No plan
Jared Gollob
Chief Medical Officer · sold 10,508 at avg $87.24
917K
8.2% of stake
Mar 2 – 4No plan
Bruce N. Jacobs
Chief Financial Officer · sold 12,471 at avg $87.50
$1.09M
5.1% of stake
Mar 210b5-1 plan
Bruce Booth
Director · sold 81,866 at avg $90.13
$7.38M
11% of stake
Feb 2510b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 30,000 at avg $90.26
$2.71M
4.3% of stake
Feb 2010b5-1 plan
Pamela Esposito
Director · sold 2,500 at avg $87.31
218K
100% of stake
Jan 2010b5-1 plan
Pamela Esposito
Director · sold 5,500 at avg $67.91
374K
100% of stake
Dec 31, 202510b5-1 plan
Nello Mainolfi
Chief Executive Officer · sold 30,000 at avg $78.06
$2.34M
4.3% of stake
Dec 17, 202510b5-1 plan
Pamela Esposito
Director · sold 27,563 at avg $82.16
$2.26M
100% of stake
Dec 10, 2025 – Dec 12, 2025No plan
Bruce Booth
Director · sold 236,588 at avg $91.72
$21.7M
26% of stake
Dec 11, 2025
Felix Baker
Director · bought 2,005,813 at avg $86.00
$172M
34% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch KYMR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with KYMR

CompareIntrinsic value

IPSCCentury Therapeutics, Inc.

$1.67+9.87%40

FDMT4D Molecular Therapeutics, Inc.

$12.28+2.76%40

AUTLAutolus Therapeutics plc

$1.38-2.83%40

PLXProtalix Biotherapeutics Inc.

$2.69+3.07%68

CGENCompugen Ltd.

$2.03+1.00%75

DNAGinkgo Bioworks Holdings Inc.

$11.65+8.27%15

AGENAgenus Inc.

$6.97+4.50%46

CSBRChampions Oncology, Inc.

$4.83+0.00%26

Held by ETFs

KYMR is in 85 US ETFs. The largest of them, with KYMR's weight in each:

Spot a number that looks wrong? Check it in KYMR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing KYMR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.